PL2838539T3 - Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych - Google Patents

Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych

Info

Publication number
PL2838539T3
PL2838539T3 PL13714917T PL13714917T PL2838539T3 PL 2838539 T3 PL2838539 T3 PL 2838539T3 PL 13714917 T PL13714917 T PL 13714917T PL 13714917 T PL13714917 T PL 13714917T PL 2838539 T3 PL2838539 T3 PL 2838539T3
Authority
PL
Poland
Prior art keywords
treatment
neurological disorders
estrogenic components
estrogenic
components
Prior art date
Application number
PL13714917T
Other languages
English (en)
Inventor
Jean-Michel Foidart
Ekaterine Tskitishvili
Original Assignee
Univ Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege filed Critical Univ Liege
Publication of PL2838539T3 publication Critical patent/PL2838539T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PL13714917T 2012-04-19 2013-04-08 Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych PL2838539T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12164741.6A EP2653163A1 (en) 2012-04-19 2012-04-19 Estrogenic components for use in the treatment of neurological disorders
PCT/EP2013/057279 WO2013156329A1 (en) 2012-04-19 2013-04-08 Estrogenic components for use in the treatment of neurological disorders.
EP13714917.5A EP2838539B1 (en) 2012-04-19 2013-04-08 Estrogenic derivatives for use in the treatment of neurological disorders.

Publications (1)

Publication Number Publication Date
PL2838539T3 true PL2838539T3 (pl) 2018-01-31

Family

ID=48050711

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13714917T PL2838539T3 (pl) 2012-04-19 2013-04-08 Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych

Country Status (20)

Country Link
US (1) US9238035B2 (pl)
EP (2) EP2653163A1 (pl)
JP (1) JP6139662B2 (pl)
CN (1) CN104379148B (pl)
AU (1) AU2013248481B2 (pl)
CA (1) CA2869902C (pl)
CY (1) CY1119603T1 (pl)
DK (1) DK2838539T3 (pl)
ES (1) ES2647111T3 (pl)
HR (1) HRP20171627T1 (pl)
HU (1) HUE034902T2 (pl)
LT (1) LT2838539T (pl)
NO (1) NO2838539T3 (pl)
PL (1) PL2838539T3 (pl)
PT (1) PT2838539T (pl)
RS (1) RS56595B1 (pl)
RU (1) RU2627846C2 (pl)
SI (1) SI2838539T1 (pl)
SM (1) SMT201700531T1 (pl)
WO (1) WO2013156329A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2714712T (pt) 2011-06-01 2016-11-08 Estetra Sprl Processo para a produção de intermediários de estetrol
SG195118A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
WO2016187558A2 (en) * 2015-05-20 2016-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Method to improve neurologic outcomes in temperature managed patients
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
LT3310346T (lt) * 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310345T (lt) * 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN107260712A (zh) * 2017-06-22 2017-10-20 中国人民解放军第三军医大学 奥培米芬在制备促进髓鞘形成和再生的药物中的应用
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
CN113243332B (zh) * 2020-02-07 2023-07-28 上海市东方医院（同济大学附属东方医院） 一种广泛脑区神经元树突发育障碍动物模型的制备与应用
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
HUP2400151A1 (hu) 2024-02-28 2025-09-28 Richter Gedeon Nyrt Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2378898A (en) * 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
PT1511496E (pt) * 2002-06-11 2007-01-31 Pantarhei Bioscience Bv Método para tratamento ou prevenção de doenças mediadas pelo sistema imunitário e formulação farmacológica para utilização nas mesmas
AU2003274943A1 (en) 2002-06-11 2003-12-22 Pantarhei Bioscience B.V. Use of estetrol and analogues for treating or preventing cardiovascular pathologies, in particular atherosclerosis
CA2623839C (en) * 2005-09-26 2013-12-17 The Regents Of The University Of California Estriol therapy for autoimmune and neurodegenerataive diseases and disorders
WO2007081206A1 (en) * 2006-01-09 2007-07-19 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
EP2155205B1 (en) * 2007-06-21 2011-12-21 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
CA2704921C (en) * 2007-11-06 2015-11-24 Ellis L. Kline Compositions and methods for treating parkinson's disease and related disorders
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用

Also Published As

Publication number Publication date
US20150133419A1 (en) 2015-05-14
CA2869902C (en) 2019-07-02
NO2838539T3 (pl) 2018-01-13
LT2838539T (lt) 2017-11-27
AU2013248481A1 (en) 2014-10-30
SMT201700531T1 (it) 2018-01-11
DK2838539T3 (da) 2017-11-27
JP2015514731A (ja) 2015-05-21
AU2013248481B2 (en) 2017-02-16
US9238035B2 (en) 2016-01-19
ES2647111T3 (es) 2017-12-19
HRP20171627T1 (hr) 2017-12-01
CN104379148A (zh) 2015-02-25
EP2838539B1 (en) 2017-08-16
RU2014145800A (ru) 2016-06-10
RU2627846C2 (ru) 2017-08-14
JP6139662B2 (ja) 2017-05-31
CY1119603T1 (el) 2018-04-04
SI2838539T1 (sl) 2017-12-29
CN104379148B (zh) 2017-08-25
RS56595B1 (sr) 2018-02-28
WO2013156329A1 (en) 2013-10-24
EP2838539A1 (en) 2015-02-25
HUE034902T2 (hu) 2018-03-28
PT2838539T (pt) 2017-11-15
EP2653163A1 (en) 2013-10-23
CA2869902A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
IL283943B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders
PL2838539T3 (pl) Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych
PL3811943T3 (pl) Związek do stosowania w leczeniu zaburzeń oczu
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
PT2919796T (pt) Utilização de akkermansia para o tratamento de distúrbios metabólicos
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
IL225668A (en) Formulations for the treatment of disorders of the upper respiratory tract
EP2869833A4 (en) TREATMENT OF INFLAMMATORY SKIN DISORDERS
IL235127A (en) Hpn-100 for use in the treatment of nitrogen-related diseases
HRP20190038T1 (hr) Derivati pantotenata namijenjeni liječenju neuroloških poremećaja
ZA201504065B (en) Therapeutic agent for keratoconjunctive disorders
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
IL234412B (en) The iloperidone metabolite for use in the treatment of psychiatric diseases
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases
PL2861568T3 (pl) Aminy trzeciorzędowe do zastosowania w leczeniu zaburzeń serca
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
EP2958570A4 (en) THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PERIANAL DISORDERS
GB201303721D0 (en) Compositions for treatment of sleep disorders
EP2970118A4 (en) COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
GB201201779D0 (en) Treatment of inflammatory disorders